141 related articles for article (PubMed ID: 12324812)
1. Extravasation of paclitaxel into breast tissue from central catheter port.
Barutca S; Kadikoylu G; Bolaman Z; Meydan N; Yavasoglu I
Support Care Cancer; 2002 Oct; 10(7):563-5. PubMed ID: 12324812
[TBL] [Abstract][Full Text] [Related]
2. Severe necrosis due to paclitaxel extravasation.
Herrington JD; Figueroa JA
Pharmacotherapy; 1997; 17(1):163-5. PubMed ID: 9017777
[TBL] [Abstract][Full Text] [Related]
3. Risk of venous access device wound complications in patients undergoing paclitaxel chemotherapy for gynecologic malignancies.
Boulay RM; Olt GJ; Podczaski ES
Gynecol Oncol; 1998 Aug; 70(2):259-62. PubMed ID: 9740701
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel extravasation causing significant delayed tissue injury.
Raley J; Geisler JP; Buekers TE; Sorosky JI
Gynecol Oncol; 2000 Aug; 78(2):259-60. PubMed ID: 10926814
[TBL] [Abstract][Full Text] [Related]
5. Skin ulceration potential of paclitaxel in a mouse skin model in vivo.
Dorr RT; Snead K; Liddil JD
Cancer; 1996 Jul; 78(1):152-6. PubMed ID: 8646711
[TBL] [Abstract][Full Text] [Related]
6. [Extravasation of cytostatics. Example of a severe complication from the use of long-term central venous catheters].
Bach F; Videbaek C; Holst-Christensen J; Boesby S
Ugeskr Laeger; 1991 Oct; 153(41):2896-7. PubMed ID: 1949309
[TBL] [Abstract][Full Text] [Related]
7. Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer.
De Angelis R; Bugatti L; Cerioni A; Del Medico P; Filosa G
Clin Rheumatol; 2003 Feb; 22(1):49-52. PubMed ID: 12605319
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel-induced "recall" soft tissue ulcerations occurring at the site of previous subcutaneous administration of paclitaxel in low doses.
du Bois A; Kommoss FG; Pfisterer J; Lück HJ; Meerpohl HG
Gynecol Oncol; 1996 Jan; 60(1):94-6. PubMed ID: 8557235
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P;
J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy extravasation from implanted ports.
Schulmeister L; Camp-Sorrell D
Oncol Nurs Forum; 2000 Apr; 27(3):531-8; quiz 539-40. PubMed ID: 10785905
[TBL] [Abstract][Full Text] [Related]
12. Symptoms and signs of an acute myocardial ischemia caused by chemotherapy with Paclitaxel (Taxol) in a patient with metastatic ovarian carcinoma.
Schrader C; Keussen C; Bewig B; von Freier A; Lins M
Eur J Med Res; 2005 Nov; 10(11):498-501. PubMed ID: 16354605
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study.
Armstrong DK; Fleming GF; Markman M; Bailey HH
Gynecol Oncol; 2006 Nov; 103(2):391-6. PubMed ID: 16626792
[TBL] [Abstract][Full Text] [Related]
14. Scleroderma induced by paclitaxel.
Pedersen JV; Jensen S; Krarup-Hansen A; Riis L
Acta Oncol; 2010 Aug; 49(6):866-8. PubMed ID: 20446892
[No Abstract] [Full Text] [Related]
15. Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer.
Linch M; Stavridi F; Hook J; Barbachano Y; Gore M; Kaye SB
Gynecol Oncol; 2008 Apr; 109(1):27-32. PubMed ID: 18262259
[TBL] [Abstract][Full Text] [Related]
16. Delayed seizure associated with paclitaxel-Cremophor el in a patient with early-stage breast cancer.
O'Connor TL; Kossoff E
Pharmacotherapy; 2009 Aug; 29(8):993-6. PubMed ID: 19637953
[TBL] [Abstract][Full Text] [Related]
17. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
[TBL] [Abstract][Full Text] [Related]
18. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.
Markman M; Liu PY; Wilczynski S; Monk B; Copeland LJ; Alvarez RD; Jiang C; Alberts D; ;
J Clin Oncol; 2003 Jul; 21(13):2460-5. PubMed ID: 12829663
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of weekly paclitaxel for advanced or metastatic breast cancer in Japan.
Horiguchi J; Rai Y; Tamura K; Taki T; Hisamatsu K; Ito Y; Seriu T; Tajima T
Anticancer Res; 2009 Feb; 29(2):625-30. PubMed ID: 19331212
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer.
Le T; Hopkins L; Baines KA; Rambout L; Al Hayki M; Kee Fung MF
Gynecol Oncol; 2006 Jul; 102(1):49-53. PubMed ID: 16375951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
